TheraRadar

Pharma Intelligence, Simplified

Landscape → Rare Disease

Immune Thrombocytopenia

253 clinical trials

137 active
/
253 total (since 2015)
29
Phase 1 Active
48 total
84
Phase 2 Active
140 total
36
Phase 3 Active
79 total
7
Phase 4 Active
18 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
Novartis 5 2 1
Jiangsu HengRui Medicine Co., Ltd. 4 4 1
argenx 4 3 1
Chongqing Peg-Bio Biopharm Co., Ltd. 2 2 0
Takeda 2 1 0
Sanofi 2 0 0
Johnson & Johnson 2 0 0
Keymed Biosciences Co.Ltd 2 0 0
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 2 0 0
Chugai Pharmaceutical 2 0 0
Qilu Pharmaceutical Co., Ltd. 1 3 0
Amgen 1 1 1
Principia Biopharma, a Sanofi Company 1 1 0
Pfizer 1 0 1
Hutchison Medipharma Limited 1 1 0
NCT07442513 RECRUITING
Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT
First Affiliated Hospital of Zhejiang University n=404
NCT07007962 RECRUITING
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Sanofi n=60
NCT05653219 ACTIVE NOT RECRUITING
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
Novartis Pharmaceuticals n=152
NCT05653349 ACTIVE NOT RECRUITING
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
Novartis Pharmaceuticals n=226
NCT04562766 ACTIVE NOT RECRUITING
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
Principia Biopharma, a Sanofi Company n=232
NCT06533098 RECRUITING
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Janssen Research & Development, LLC n=50
NCT06449651 RECRUITING
A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Janssen Research & Development, LLC n=39
NCT07194850 RECRUITING
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
argenx n=24
NCT06544499 RECRUITING
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
argenx n=69
NCT06948318 RECRUITING
A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Takeda n=150
NCT06722235 RECRUITING
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Takeda n=171
NCT03937154 ACTIVE NOT RECRUITING
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
Amgen n=145
NCT07059000 RECRUITING
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
Kedrion S.p.A. n=40
NCT06962631 RECRUITING
V-IMMUNE® for Immune Thrombocytopenia
On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA. n=31
NCT04812925 ACTIVE NOT RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
argenx n=173
NCT06456528 RECRUITING
QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia
Qilu Pharmaceutical Co., Ltd. n=235
NCT07233213 RECRUITING
An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia
Grand Shuyang Life Sciences (Chengdu) Co., Ltd. n=36
NCT07286032 NOT YET RECRUITING
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd. n=150
NCT07278908 NOT YET RECRUITING
Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China n=248
NCT06507436 RECRUITING
The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery
Jiangsu HengRui Medicine Co., Ltd. n=101
NCT07216079 ACTIVE NOT RECRUITING
Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan
Sanofi n=4
NCT04225156 ACTIVE NOT RECRUITING
A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
argenx n=101
NCT07051915 NOT YET RECRUITING
The Holistic Study
Ostfold Hospital Trust n=220
NCT05325593 ACTIVE NOT RECRUITING
Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla n=129
NCT06900920 RECRUITING
A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=199
NCT05864014 ACTIVE NOT RECRUITING
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.
Jiangsu HengRui Medicine Co., Ltd. n=213
NCT06913374 NOT YET RECRUITING
The Study of Different Cycles of High-dose Dexamethasone in the Treatment of ITP
Shandong University n=118
NCT05029635 ACTIVE NOT RECRUITING
Phase III Study on HMPL-523 for Treatment of ITP
Hutchison Medipharma Limited n=272
NCT06759636 NOT YET RECRUITING
FRIENDS-01：A Multicenter Open-label Randomized Controlled Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11
The First Affiliated Hospital with Nanjing Medical University n=88
NCT06202625 RECRUITING
Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT
Peking University People's Hospital n=142
NCT04915482 RECRUITING
TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
Institute of Hematology & Blood Diseases Hospital, China n=94
NCT06440824 NOT YET RECRUITING
A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin
Shandong University n=60
NCT06004856 RECRUITING
Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia
Beijing InnoCare Pharma Tech Co., Ltd. n=195
NCT02707497 RECRUITING
The Effect of REcombinant Human Thrombopoietin (rhTPO) on Sepsis Patients With aCUte Severe thrombocytopEnia
Ruilan Wang n=200
NCT05338190 RECRUITING
Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia
Assistance Publique - Hôpitaux de Paris n=132
NCT04968899 RECRUITING
IgIV Plus Prednisone vs High-dose Dexamethasone for ITP
Assistance Publique - Hôpitaux de Paris n=272
NCT03362177 COMPLETED
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
Amgen n=165
NCT04516967 COMPLETED
Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
Sobi, Inc. n=75
NCT05369208 COMPLETED
Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP
Sobi, Inc. n=19
NCT04132050 COMPLETED
A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788
Kissei Pharmaceutical Co., Ltd. n=34
NCT03939637 COMPLETED
Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
Baylor College of Medicine n=122
NCT04737850 COMPLETED
Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd. n=100
NCT03976882 COMPLETED
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.
Jiangsu HengRui Medicine Co., Ltd. n=129
NCT04200456 TERMINATED
A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
UCB Biopharma SRL n=33
NCT04188379 COMPLETED
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
argenx n=131
NCT06288932 COMPLETED
Outcome Study of Conventional Steroids Vs. Steroids Combined with Mycopehnolate in Newly Diagnosed Immune Thrombocytopenia Purpura.
National Institute of Blood and Marrow Transplant (NIBMT), Pakistan n=118
NCT04687072 COMPLETED
A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
argenx n=207
NCT05554913 COMPLETED
Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia
Qilu Pharmaceutical Co., Ltd. n=63
NCT05422365 COMPLETED
Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults
Biopharma Plasma LLC n=32
NCT05492409 COMPLETED
Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients
AO GENERIUM n=160
NCT02868099 COMPLETED
Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)
Kyowa Kirin China Pharmaceutical Co., Ltd. n=203
NCT05220878 COMPLETED
Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP
AO GENERIUM n=160
NCT04596995 TERMINATED
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
UCB Biopharma SRL n=43
NCT05261646 WITHDRAWN
A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.
NCT03471078 COMPLETED
Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers
Sobi, Inc. n=122
NCT04224688 TERMINATED
A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
UCB Biopharma SRL n=30
NCT05851027 COMPLETED
Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia
Qilu Pharmaceutical Co., Ltd. n=50
NCT03809481 TERMINATED
Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban
Aspen Global Incorporated n=7
NCT05621330 COMPLETED
Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia
Qilu Pharmaceutical Co., Ltd. n=216
NCT03156452 COMPLETED
Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate
University Hospitals Bristol and Weston NHS Foundation Trust n=123
NCT05566990 COMPLETED
A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj.10% in Primary Immune Thrombocytopenia (ITP)
SK Plasma Co., Ltd. n=34
NCT03222843 COMPLETED
Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient
Jiangsu HengRui Medicine Co., Ltd. n=424
NCT03515096 COMPLETED
Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT
Shenzhen Second People's Hospital n=98
NCT02444728 TERMINATED
Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE
Chinese SLE Treatment And Research Group n=50
NCT05046327 WITHDRAWN
Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months
Sobi, Inc.
NCT03164915 COMPLETED
A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP)
SK Plasma Co., Ltd. n=37
NCT02578901 COMPLETED
American Trial Using Tranexamic Acid in Thrombocytopenia
University of Washington n=330
NCT03391856 TERMINATED
Prolonged Isolated Thrombocytopenia After Allo-SCT : N-acetyl-L-cysteine (NAC) Versus Supportive Therapy
Peking University People's Hospital n=15
NCT01663441 COMPLETED
A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11
Beijing Northland Biotech. Co., Ltd. n=62
NCT04274452 WITHDRAWN
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)
argenx
NCT02487563 COMPLETED
Prospective Study of Patients With Thrombocytopenia Following HSCT
The First Affiliated Hospital of Soochow University n=97
NCT03326843 TERMINATED
Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure
Sobi, Inc. n=4
NCT02391272 COMPLETED
A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy
Shandong University n=31
NCT02859909 COMPLETED
This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP)
Biotest n=34
NCT02389621 COMPLETED
Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures
Shionogi n=215
NCT02649504 WITHDRAWN
Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia
Weill Medical College of Cornell University
NCT03343847 WITHDRAWN
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.
Amgen
NCT02914054 COMPLETED
Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone
Isfahan University of Medical Sciences n=36
NCT01609452 WITHDRAWN
MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP
Anthera Pharmaceuticals

Data: ClinicalTrials.gov